Medicines for Europe’s podcast exploring the off-patent medicines world

Episode 5: Preventing shortages in Europe through resilient medicines policies

Not only regulatory efficiency measures are critical to reduce pressure on the off-patent sector, but also the implementation of sustainable policies, the lowering of cost containment measures or the adoption of new pricing models to ensure a healthy, competitive, resilient and diversified generic supply can help preventing shortages in the off-patent sector.

We take a closer look at the origins of this knotty situation in order to better understand its drivers, identify possible solutions and understand what new opportunities the new European Pharmaceutical legislation may offer.

Amazon MusicApple Podcast  – Castbox Google Podcasts OverCastPocket CastsRadioPublic  – YouTubeSpotify Stitcher

If would like to know more about this topic, you can dive into the resources mentioned during this episode:

Episode 4.II: Inflation: How can it affect supply of medicines? Part II

We need a shift to pricing policies that ensure healthy market competition and prevent undesired effects of existing pricing mechanisms, allowing patients to continue to have access to a broad range of therapeutic options as well as guaranteeing that generic competition remains healthy on the long term.

In this episode, we will explore new pricing policy models that may be an adequate response to deliver a sustainable supply of medicines to patients considering the current circumstances (COVID-19 recovery, inflation, increasing cost of goods).

Amazon MusicApple Podcast  – Castbox Google Podcasts OverCastPocket CastsRadioPublic  – YouTubeSpotify Stitcher

 

Episode 4.I: Inflation: How can it affect supply of medicines? Part I

Inflation affects the off-patent medicines industry disproportionately since off-patent medicines naturally have smaller profit margins thanks to competition between multiple manufacturers and off-patent medicine price regulations do not allow companies to adjust prices, unlike other industries where prices have risen in line with inflation and increasing costs. We need to act now to ensure the availability of medicines in all European countries.

In this first half of this podcast episode on inflation, we would like to explore the challenges and impact for the off-patent pharmaceutical industry related to inflation, as well as address possible solutions to tackle the consequences of inflation in the off-patent medicines sector.

Amazon MusicApple Podcast  – Castbox Google Podcasts OverCastPocket CastsRadioPublic  – YouTubeSpotify Stitcher

Episode 3: The Nurses’ voice on Biosimilar Medicines. An opportunity for integrated care

Conversations on EU Pharma is back with a third episode we will explore the role played by specialised nurses in delivering positive patient outcomes with biologic therapies and the development of integrated care for patients living with Non-Communicable Diseases (NDC), starting with an overview on the impacts of Covid-19 on the nursing community. If would like to know more about this topic, you can dive into the resources mentioned during this episode:

Listen to the episode on: Amazon MusicApple Podcast  – Castbox Google Podcasts OverCastPocket CastsRadioPublic  – YouTubeSpotify Stitcher

Episode 2: On the way to equitable access to medicines in Central and Eastern Europe

The second episode of Conversations on EU Pharma will focus on equitable access to medicines for patients and how the path to timely access to treatment can be challenging.  With a focus on Central and Eastern Europe and the consequences of the pandemic on healthcare systems, our host and honourable speakers exchange their views on thoughtful policy reforms to ensure equitable access to medicines for all patients across Europe.  To learn more, consult our report Removing access barriers in Central and Eastern Europe: How can we ensure equitable access to medicines for all European patients?  Thank you for listening to us.  Please note that the episode was recorded before the Russia-Ukraine War, which is also impacting many Central and Eastern European countries.   Listen to the episode on: Amazon MusicApple Podcast  – Castbox Google Podcasts OverCast – Pocket Casts RadioPublic  YouTube Spotify Stitcher

Episode 1: Value Added Medicines: a patient-centric approach to healthcare

In our very first episode, we will talk about Value Added Medicines (VAMs) to understand what benefits they can deliver to patients and the whole healthcare community. If this episode piques your curiosity, visit the VAMs section on our website for more information. To learn more about the benefits of VAMs for patients with respiratory diseases, check Monica Fletcher‘s publications and take a look at the Asthma UK Centre for Applied Research  and at BREATHE – The Health Data Research Hub for Respiratory Health. Listen to the episode on: Amazon MusicApple Podcast  – Castbox Google Podcasts Pocket Casts RadioPublic  YouTube Spotify Stitcher